RT Journal Article
T1 Maternal Supplementation with N-Acetylcysteine Modulates the Microbiota-Gut-Brain Axis in Offspring of the Poly I:C Rat Model of Schizophrenia
A1 Romero Miguel, Luis Diego
A1 Casquero-Veiga, Marta
A1 Fernández, Javier
A1 Lamanna Rama, Nicolás
A1 Gómez Rangel, Vanessa
A1 Gálvez-Robleño, Carlos
A1 Santa Marta, Cristina
A1 Villar, Claudio J.
A1 Lombo, Felipe
A1 Abalo, Raquel
A1 Desco Menéndez, Manuel
A1 Soto Montenegro, Mª Luisa
AB The microbiota-gut-brain axis is a complex interconnected system altered in schizophrenia. The antioxidant N-acetylcysteine (NAC) has been proposed as an adjunctive therapy to antipsychotics in clinical trials, but its role in the microbiota-gut-brain axis has not been sufficiently explored. We aimed to describe the effect of NAC administration during pregnancy on the gut-brain axis in the offspring from the maternal immune stimulation (MIS) animal model of schizophrenia. Pregnant Wistar rats were treated with PolyI:C/Saline. Six groups of animals were studied according to the study factors: phenotype (Saline, MIS) and treatment (no NAC, NAC 7 days, NAC 21 days). Offspring were subjected to the novel object recognition test and were scanned using MRI. Caecum contents were used for metagenomics 16S rRNA sequencing. NAC treatment prevented hippocampal volume reduction and long-term memory deficits in MIS-offspring. In addition, MIS-animals showed lower bacterial richness, which was prevented by NAC. Moreover, NAC7/NAC21 treatments resulted in a reduction of proinflammatory taxons in MIS-animals and an increase in taxa known to produce anti-inflammatory metabolites. Early approaches, like this one, with anti-inflammatory/anti-oxidative compounds, especially in neurodevelopmental disorders with an inflammatory/oxidative basis, may be useful in modulating bacterial microbiota, hippocampal size, as well as hippocampal-based memory impairments.
PB MDPI
SN 2076-3921
YR 2023
FD 2023-04-20
LK https://hdl.handle.net/10016/38869
UL https://hdl.handle.net/10016/38869
LA eng
NO M.L.S.-M. was supported by the Ministerio de Ciencia e Innovación, Instituto de SaludCarlos III (project number PI17/01766, and grant number BA21/00030), co-financed by the EuropeanRegional Development Fund (ERDF), “A way to make Europe”; project PID2021-128862OB-I00funded by MCIN/AEI/10.13039/501100011033/FEDER, UE, CIBER de Salud Mental-Instituto deSalud Carlos III (project number CB07/09/0031); Delegación del Gobierno para el Plan Nacionalsobre Drogas (project number 2017/085, 2022/008917); and Fundación Alicia Koplowitz. D.R.-M.was supported by Consejería de Educación e investigación, Comunidad de Madrid, co-funded bythe European Social Fund “Investing in your future” (grant, PEJD-2018-PRE/BMD-7899). M.C.-V.was supported by a predoctoral grant from Fundación Tatiana Pérez de Guzmán el Bueno. N.L.-R.was supported by the Instituto de investigación Sanitaria Gregorio Marañón, “Programa Intramuralde Impulso a la I+D+I 2019”. V.G.-R was supported by Consejería de Educación e investigación,Comunidad de Madrid, co-funded by the European Social Fund “Investing in your future” (grant,PEJD-2017-TL/BMD-7385). C.G.-R. was supported by Universidad Rey Juan Carlos (PREDOC20-054). R.A. was supported by Ministerio de Ciencia, Innovación y Universidades (grant numberPID2019-111510RB-I00) and Grupo Español de Motilidad Digestiva (Beca Allergan, 2017). M.D. workwas supported by Ministerio de Ciencia e Innovación (MCIN) and Instituto de Salud Carlos III(PT20/00044). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministeriode Ciencia e Innovación (MCIN) and the Pro CNIC Foundation and is a Severo Ochoa Center ofExcellence (SEV-2015-0505). J.F. was supported by “Contrato Intramural Postdoctoral” from FINBA(Principado de Asturias, Spain). F.L. was supported by Ayudas para grupos de investigación deorganismos del Principado de Asturias (SV-PA-21-AYUD/2021/51347).
DS e-Archivo
RD 30 jun. 2024